![]() Contact Us |
![]() Contact Us |
![]() Contact Us |
![]() Contact Us |
![]() |
IATDMCT PresidentYusuke Tanigawara |
Dr. Yusuke Tanigawara is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan. He teaches clinical pharmacology to medical students and post-graduate students. He is an Adjunct Faculty of University of Florida, College of Pharmacy.
He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. He started working in the field of TDM since 1985 when he joined with Kyoto University Hospital as a faculty member responsible for TDM. His research interests include pharmacokinetics, pharmacodynamics and optimal dosing algorithms for personalized medicine. Oncology and infectious diseases are his major fields for research. He applied population pharmacokinetic and pharmacodynamic modeling to a number of new drug development as well as rational use of drugs for patient care such as clinical implementation of TDM. Recently, he also investigates multi-omics biomarkers including pharmacogenomics, proteomics and metabolomics as a novel indicator to predict responder/non-responder variation to drug therapy. He published more than 180 peer-reviewed original articles and 282 book chapters and review articles. He was distinguished as one of the “ISI Highly Cited Researchers” by Thomson Reuters ISI database.
He served as Secretary of the IATDMCT for 4 years, and Chair of the 15th Congress of IATDMCT in Kyoto, 2017. He was a past President of Japanese Society of Therapeutic Drug Monitoring (JSTDM).
![]() |
IATDMCT President-ElectDario Cattaneo |
Employment
Academic commitments
Education & Certification:
Professional Activities
Awards
Publications / scientific activities
Main clinical/research activities
Vision Statement
I envisage the future of the IATDMCT society as the key player for the tailoring of drug therapy in increasingly complicated patients (elderly, with comorbidities and heavy polypharmacy) at the bedside, taking advantage from the presence of active members with excellences and expertise in several fields. The accomplishment of this task requires, however, a day-by-day, two-way strict collaboration with specialists from different medical disciplines. In other words, the labs need to meet/match the clinics!
![]() |
IATDMCT SecretaryMaria Shipkova |
Employment
Education & Certification:
Professional Activities
Why would you be a good member of IATDMCT Council
As a longstanding member of IATDMCT for (>20 years) and somebody who had have the privilege to serve this Association at various positions over the past years I am glad to know many IATDMCT members and enjoy networking within IATDMCT. I hope that I have been able to convince with organizational-, communication-skills and persistence during my services and will be honored to continue my efforts for IATDMCT as a member of the Council.
![]() |
IATDMCT TreasurerDenise Anne McKeown |
Since September 2012, Denise has worked as a Forensic Toxicologist at Forensic Medicine and Science (FMS), University of Glasgow. Prior to this she worked for just under 10 years at Analytical Services International, St George’s - University of London under the supervision of IATDMCT Past-President Professor David W Holt. In both positions she has pursued her interest in bioanalytics; she specialises in the development and validation of hyphenated chromatographic and mass-spectrometric methods for the qualitative and quantitative detection of drugs, their metabolites and endogenous compounds for application in the areas of forensic and clinical toxicology. In her current position Denise is also a reporting Forensic Toxicologist and Expert Witness responsible for interpretation and communication of toxicological finding to the Scottish Courts.
For 12 years, Denise has been an active member of IATDMCT with a successful committee history. During a decade on the Young Scientists Committee as Vice-Chair then Chair, YS membership increased from 8 to 296 members. Denise was also the founding chair of the very active Communications Committee, who are integral to association activities. Denise looks forward to devoting the same enthusiasm to her role as IATDMCT Treasurer.
Employment:
Education & Certification:
Professional Activities:
![]() |
IATDMCT Past PresidentTeun van Gelder |
Dr. Teun van Gelder is an internist-nephrologist and clinical pharmacologist. He was trained in internal medicine and nephrology at the Erasmus Medical Center, and completed his thesis in 1996 on the use of anti-interleukin-2 receptor monoclonal antibodies in solid organ transplantation. As a post-doctoral scientist, he worked in the Transplantation Immunology Laboratory of Dr. Randall E. Morris at Stanford University (1998-2000), and was awarded the Young Investigator Award from the American Society for Transplantation for his work during this time.
Between 2000 and 2019 he worked in the Departments of Hospital Pharmacy and Internal Medicine at the Erasmus Medical Center in Rotterdam, the Netherlands. In 2010, at Erasmus Medical Center he was appointed Professor in Clinical Pharmacology. His research at the Erasmus Medical Center was focused on clinical pharmacology and therapeutic drug monitoring. He was the chairman of the Dutch Society for Clinical Pharmacology & Biopharmacy, the secretary of the Dutch Society for Transplantation, and the President of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.
In December 2019 Teun van Gelder accepted a new position in Leiden University Medical Center (LUMC). He was appointed Professor in Drug Discovery & Development. LUMC, Leiden Institute of Chemistry, Leiden Academic Centre for Drug Research (LACDR), Centre for Human Drug Research (CHDR) and Leiden Bio Science Park (LBSP) together have the expertise and facilities for the design, development and testing of new innovative drugs. This environment is unique in the Netherlands, and provides an excellent basis for drug discovery and drug development. In his role as an experienced internist – clinical pharmacologist Teun will make an important contribution to Academic Pharma.
![]() |
Director of EducationDebbie Marriott |
Current Appointments
Certifications
Current Memberships - Professional Societies
Selection of Professional Activities (all to date unless otherwise indicated)
![]() |
Director of EducationMarkus Meyer |
Prof. Dr. Markus R. Meyer is a full Professor of Pharmacology & Toxicology at the Faculty of Medicine and at the Faculty of Pharmacy, Saarland University and head of the Department of Experimental and Clinical Toxicology at the Saarland University in Homburg, Germany. After he was promoted to PhD and gained his habilitation (venia legendi in pharmacology and toxicology) from the Saarland University, he moved to the Department of Clinical Pharmacology at the Karolinska Institutet in Stockholm, Sweden and thereafter to the Department of Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University Hospital, Germany. His main area of research is analytical toxicology including in-vitro and in-vivo toxicokinetics.
He has published over 120 peer-reviewed original papers or review articles and received several international and national scientific awards amongst them the TIAFT Achievement Award and the GTFCh Young Scientist Award. Besides IATDMCT, Prof. Meyer is member of several international and national scientific societies such as the TIAFT, GTFCh, DGPT, and DGMS. He is currently IATDMCT board member and chair of the YS committee of the IATDMCT as well as vice chair of the TIAFT YS committee.
![]() |
Director of EducationStaffan Rosenborg |
Staffan Rosenborg graduated as an MD from Karolinska Institutet in 1996. He became a specialist in Nephrology in 2003 and in Clinical Pharmacology in 2007. Dr Rosenborg defended his PhD thesis “CYP2C dependent drug metabolism in vivo – influence of genetics and drug interactions” in 2010. Prof Teun van Gelder was the external examiner.
Dr Rosenborg was Head of Residents and Director of post-graduate training in Clinical Pharmacology at the Karolinska University Hospital between 2010 and 2013. From 2013 he has been the Head of the Clinical Pharmacology Trial Unit (CPTU) at the same hospital. The CPTU is a phase-I trial unit certified for first-in-human trials. Dr Rosenborg was awarded the Swedish Diploma in Clinical Trials in June 2016.
He is the secretary of the Swedish Foundation for Clinical Pharmacology and Pharmacotherapy and is also one of two Swedish representatives in the Section for Pharmacology of the Union Européenne des Médecines Spécialistes (UEMS). He has more than 500 lecturing hours, has organized courses in clinical pharmacokinetics and has participated in courses on leadership in postgraduate education.
Dr Rosenborg has some 20 peer reviewed publications in international journals and some 15 papers in Swedish journals. His areas of expertise include: different aspects of nephropharmacology (including drug dosing in dialysis), immunosuppressive drugs, pharmacokinetics, therapeutic drug monitoring, clinical trial design and conduct.
![]() |
IATDMCT CouncillorRyuji Kato |
Dr. Ryuji Kato is an Associate Professor of Cardiovascular Pharmacotherapy and Toxicology at Osaka University of Pharmaceutical Sciences, Osaka, Japan. He completed his master’s degree in 2000 at Osaka University and began his career as a pharmacist at the Yokkaichi Social Insurance Hospital (Mie, Japan). He then moved to Osaka University of Pharmaceutical Sciences as an Assistant Professor. In 2008, he received his PhD in Pharmaceutical Sciences.
His research interests primarily include the appropriate use of pharmaceutical products. He has conducted extensive research on pharmacokinetics, drug-drug interactions (chelation complexes, drug-drug interactions on cytochrome P450 or via transporters), and serious adverse side effects (QT prolongation, drug induced liver injury, interstitial pneumonia, Stevens-Johnson syndrome, and toxic epidermal necrolysis).
He is the author or co-author of approximately 70 peer-reviewed manuscripts. Dr. Kato is a member of the following academic societies: International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Japanese Society of Therapeutic Drug Monitoring (JSTDM), Society of Toxicology (SOT), Pharmaceutical Society of Japan, and Japanese Society of Nephrology and Pharmacotherapy (JJNP). He has been a member of IATDMCT Communication Committee since 2015 and is an inspector for JSTDM.
![]() |
IATDMCT CouncillorChristophe Stove |
Christophe Stove, PharmD, PhD, is Associate Professor at the Department of Bioanalysis at Ghent University (Belgium). After a cell and molecular biology-oriented PhD and postdoc, he embarked upon bioanalysis in 2007 and became head of the Laboratory of Toxicology at the Faculty of Pharmaceutical Sciences in 2014. Besides teaching several courses, he directs the Lab’s service activities (forensic toxicology and reference lab activities (Ref4U)) and steers the research. The latter covers applied cell biology, as well as bioanalysis, with topics linked to the development of bio-assays as an alternative drug screening approach in forensic toxicology, to vitamer analysis, or to microsampling applications and associated challenges. He has over 125 publications, many of which in leading journals, and has an h-index of 28. He is active as a Board/Council Member of several national and international organizations (including TIAFT and IATDMCT).
![]() |
IATDMCT CouncillorNicolas Venisse |
Nicolas Venisse got his PharmD from the University of Bordeaux, France in 1999. He completed his PhD in Pharmaceutical Sciences at the University of Poitiers. He also received accreditation to supervise research from the University of Poitiers. He is expert at the court of appeal of Poitiers.
He currently works at the Toxicology and Pharmacokinetics department at the University Hospital of Poitiers. He is also a member of the HEDEX (Health - Endocrine Disruptors – Exposome) research group at the Clinical Investigation Center of Poitiers (CIC INSERM 1402).
He is a member of several professional organizations including : Société Française de Pharmacologie et Thérapeutique and IATDMCT. He is the current chair of the Toxicology and Environmental Health scientific committee at IATDMCT. He is a member of the French National Academy of Pharmacy (Académie Nationale de Pharmacie), Environmental Health Committee (6éme section, Santé Environnementale).
He has over 40 peer-reviewed publications and 10 book chapters. His areas of expertise include: environmental toxicology, pharmaco- and toxico-kinetics, bioanalysis and PK/TK modeling.
![]() |
IATDMCT CouncillorMiao Yan |
Employment
Education & Certification
Professional Activities